Medical Devices
Technology
Health
Masimo
$139.309876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$139.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.25 (0.91%) Today
+$0.33 (0.24%) After Hours
Why Robinhood?
You can buy or sell Masimo and other stocks, options, ETFs, and crypto commission-free!
About
Masimo Corporation Common Stock, also called Masimo, is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. Read More The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.
CEO
Employees
4,500
Headquarters
Irvine, California
Founded
1989
Market Cap
7.41B
Price-Earnings Ratio
39.67
Dividend Yield
0.00
Average Volume
486.55K
High Today
$139.74
Low Today
$137.92
Open Price
$138.71
Volume
80.69K
52 Week High
$147.91
52 Week Low
$96.14
Collections
Medical Devices
Technology
Health
Medical
Gas
Oil and Gas
Fossil Fuel
US
News
Yahoo FinanceMay 22
Here's Why You Should Buy Masimo Stock Right Now
Masimo Corporation MASI has been gaining investor confidence on continued positive results. Over the past year, the stock has rallied 41.9% against the industry’s 3.3% decline. Also, the company has outperformed the S&P 500’s 3.6% rise. The company has an encouraging earnings surprise history, having outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average being 6.6%. Notably, the consecutive beats underline its operating efficiency. A solid view for 2019 and a slew of devel...
Yahoo FinanceMay 21
Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring
Masimo Corporation MASI recently announced that it has received a 510(k) clearance from the FDA for Radius PPG. This FDA nod will prove beneficial for the company as Radius PPG utilizes the power of clinically proven Masimo SET technology that will deliver accurate measurement while the patients are on the move.
Seeking AlphaMay 20
Masimo's SpHb device effective in noninvasive hemoglobin monitoring
Masimo (NASDAQ:MASI) reports the results of a study in Beijing evaluating the ability Masimo SpHb (noninvasive hemoglobin) to estimate when to conduct invasive hemoglobin measurement to detect possible anemia in patients undergoing spine or cytoreductive surgery.
Price Paid on Robinhood
37% Higher
Right Now
52 Week Low
$96.14
Average Price Paid
$101.61
52 Week High
$147.91
Earnings
$0.53
$0.63
$0.73
$0.83
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 31, After Hours